While RASD1 expression generally remains low in most cancers compared to normal tissues, we observed the opposite in THYM, a cancer with a low incidence of KRAS mutations, and UCEC, a cancer in which patients with KRAS mutations exhibit a more favorable prognosis [23]. This evidence concerns the gene KRAS and cancer.